
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions regarding Oxford Biomedica Plc (OXB) have showcased a mixture of anticipation and apprehension ahead of the company’s upcoming financial results presentation set for April 9, 2024. Notably, investors are focusing on the recent announcements and presentations, with one participant highlighting, “Lucinda’s presentation next week is anticipated to mirror Frank's previous corporate presentation,” suggesting continuity in messaging but also expressing concerns about the lack of fresh insights. There is a sentiment that the market has not fully priced in expected developments, with discussions indicating uncertainty about the company’s future contracts and partnerships, especially in relation to ongoing projects with Bristol-Myers Squibb (BMS).
Financially, OXB has faced challenges, particularly with a reported one-time expense of $5.4 million associated with BMS’s transition to suspension lentiviral vector manufacturing. This has led to concerns expressed by participants regarding potential impacts on stock performance, with comments like, “If it turns out as threatened, OXB will quickly transition as many US-destined products as possible to Boston for manufacture.” Despite these challenges, some investors maintain a degree of optimism, referencing OXB's past performance and emphasizing the importance of maintaining key support levels in stock price. Overall, while investor sentiment remains cautiously optimistic regarding the company's long-term potential, there is a palpable anxiety about the short-term performance and communication from leadership.
Show more
Oxford Biomedica PLC (OXB), a leading contract development and manufacturing organisation (CDMO) in the cell and gene therapy sector, announced the total voting rights as of February 28, 2025, consisting of 105,975,816 ordinary shares, with no shares held in treasury. This information allows shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
Additionally, the company is set to participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, where Chief Financial Officer Dr. Lucinda Crabtree will be featured in a fireside chat. The event can be streamed live on OXB's website, with a replay available afterward, signaling the company's commitment to transparency and engagement with its investors. These developments underline Oxford Biomedica's active presence in the healthcare sector, reinforcing its strategic initiatives and focus on enhancing shareholder communication.
Show more
Columbia Threadneedle Management Limited is wholly owned by Columbia Threadneedle Holdings Limited, which is wholly owned by Columbia Threadneedle Group (Management) Limited, which is wholly owned by Columbia Threadneedle Group (Holdings) Limited, which is wholly owned by Columbia Threadneedle AM (Holdings) Plc, which is wholly owned by Columbia Threadneedle (Europe) Limited, which is wholly owned by Columbia Threadneedle Investments UK International Limited, which is wholly owned by Ameriprise Financial, Inc.which which which |
Well,i'll take it as reassuring without going too deeply into the rather opaque world of holding declarations.There can be an unsatisfactory delay between time of dealing and notification of a share holding and i would guess that this share purchase was the reason why the shares shot from 390 to around 440 in short order the week before last.It could be the large buyer which Dominic C understood was in the wings a fortnight back. |
No great surprise that low, and better than the techmark index I suppose :) |
Well spotted Cousin. |
So Columbia Threadneedle (per the RNS detail) were down as 3.06% in the OXB annual report, so have built another 2% over the last 6 months or so. Their business also now includes the old F&C/I&S/BMO funds but not sure where the OXB position held. |
Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota.[1] It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.[1]As of April 2022, more than 80% of the company's revenue came from wealth management.[1][2]Ame |
Honestly never heard of them Tricky, but |
So our accumulator is unveiled. |
Not impossible - interesting just how few firms from the health sector are linked to FTSE 250...look at the big investors in this area e.g. Mercantile IT close to zero investment in this sector and as you look at all the other names it follows a very similar pattern. |
takeiteasy, |
Not all of us.... |
All this talk about US politics has scared all the OXB punters off today - they must read into this BB that the die hards have lost interest and are bored :) |
Time to let politics go and concentrate on our favourite subject, dear OXB. Til the morning, yn y bore! Looking forward to fireworks this week!!!! |
I promise to get back to OXB tomorrow and shut up about current events (or at least give it a try). |
I have never looked to political leaders to be examples of moral rectitude or providers of moral guidance.From feted heroes of distant history,to the likes of Lloyd George and JFK,flawed individuals have achieved power.I don't even expect to learn the complete truth.Russian missiles in Cuba in 63 but no mention of US missiles in Turkey,weapons of mass destruction in Iraq ,we are drip fed selective information so we will conclude what powerful lobbies,political and military,want us to believe.I'm not a conspiracy theorist but i do believe that the powers that be,invariably connive to keep the general public pretty much in the dark,exaggerating this and underplaying that,according to their agenda.A benign dictatorship seems increasingly acceptable in my advancing years :) |
sj, |
This is just a bit of oversimplified misinformation that is popular on twitter and actually stands up to very little scrutiny. |
Yes GJ , it's amazing that anyone with 34 felony convictions and a rape conviction, who incited an insurrection, sold "Top-Secret" files to foreign nations, and an inveterate lying thief could EVER be considered a candidate for POTUS. I guess we live and learn...🤔 |
The office of President of the USA should be greater than the President who holds it. Many poor presidents have at least held the office well. Others have demeaned the office they serve. |
Harry,Yes, I did watch the videos of the riots, and they very much confirmed all that I had read and seen before.Some people acted in what appeared to be almost bemused good nature, but others were out for blood. However, five people died, so it was serious, but Trump thought not. That sums him up. I'm a full blooded right of center libertarian, but could never support a man like that, even in the face of a Harris shaped alternative.And yes, you are right about the risks of Greece: like many previously communist led countries, it has history of expropriation! My (half hearted) musings have everything in excess of living expenses simply moved straight away from the SIPP into Overseas Bonds, domiciled in Guernsey, which would remove that risk. (Anyone else here got experience of those vehicles? SIPPs and ISA's have pushed them off the radar, but with labour in power I think that may change).And yes too to your observations regarding European migration: almost (?!) as much a mess as in the UK. At the moment, Greece (Crete) is home to a huge number of (illegal) migrants from Albania, Morocco, and Georgia. Everyone else moves on, hoping to get to Germany, Sweden or the UK, which are seen as the easy touches. |
red, |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 302.50 |
Offer Price | 304.00 |
Open | 302.50 |
Shares Traded | 261,442 |
Last Trade | 09:00:34 |
Low - High | 301.50 - 304.00 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7380 |
PE Ratio | -1.70 |
Market Cap | 312.59M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions